Clinical efficacy of drugeluting stents for femoral popliteal arteriosclerosis obliterans
10.3969/j.issn.1006-5725.2023.21.017
- VernacularTitle:药物洗脱支架治疗股腘动脉硬化闭塞症的效果分析
- Author:
Haozhe ZHENG
1
;
Bing WANG
;
Xiaoyang NIU
;
Wenjun CUI
;
Ling WANG
;
Zhengzuo LÜ
Author Information
1. 郑州大学第五附属医院血管外科(郑州 450052)
- Keywords:
arteriosclerosis obliterans;
drug-eluting stents;
baremetalstent;
femoral popliteal artery
- From:
The Journal of Practical Medicine
2023;39(21):2796-2801
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of drug eluting stents vs metal bare stents for femoral popliteal arteriosclerosis obliterans.Methods The clinical data of 47 patients with femoral popliteal arte-riosclerosis obliterans receiving endovascular therapy from October 2020 to June 2021 were retrospectively ana-lyzed.A total of 24 cases received drug-eluting stents(DES group)and 23 cases underwent metal bare stents(BMS group).Results All patients successfully completed the operation without any adverse events.There was no statistical difference in ABI between the DES group and the BMS group at 7 days and 3 months after surgery,and ABI growth value of the DES group was higher than that of the BMS group at 6,12 and 24 months after surgery(P<0.05).There was no significant difference in the primary patency rate at 6 months after surgery,However,the primary patency rate in DES group was higher than that in BMS group at 12 and 24 months after surgery(91.7%vs.65.2%,83.3%vs.56.5%,P<0.05).For the target lesion revascularization rate of the two groups,DES group had a significant advantage over BMS group(4.0%vs.26.1%,P<0.05).Conclusion DES had better clinical efficacy and advantage over bare metal stent for the treatment of femoral popliteal arteriosclerosis obliterans.
